Advanced Transit Dynamics News
News on Advanced Transit Dynamics (Ticker: JNJ) continually updated from thousands of sources around the net.
Trending on the Topix Network
As part of another diary I brought up several excellent sources of Truth, Reality and Knowledge and today I re-post that information purely for it's own sake because I truly believe - it's worth the effort and benefit that it may impart to all those who are willing to listen and capable of comprehending the message.
Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.
Medivir AB announces that the global second quarter net sales of Olysio amounted to 831 MUSD, of which 725 MUSD were sales in the USA.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Stock futures edged higher Tuesday as investors digested mixed U.S. retail sales data and several corporate earnings reports.
This Oct. 16 2012, file photo, shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St. Petersburg, Fla.
Johnson & Johnson is well known around the dividend growth investing community with over 50 consecutive years of dividend increases.
Waiting for a recovery in the orthopedic market isn't exactly waiting for Godot, but it has been frustrating all the same.
Johnson & Johnson is slated to report 2Q 2014 earnings before the opening bell on Tuesday, July 15th.
American conglomerates that want a piece of the tax-inversion deal bonanza may start turning to a new tactic.
In the latest instalment of our Head-To-Head series, we pitch two companies from the health care sector, Johnson & Johnson and Covidien, against one another.
Just nine months after buying the east-end Johnson & Johnson factory, Energizer Holdings announced Tuesday it will shut down the facility beginning next summer.
Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates for the treatment of cancer, announced today the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development.
Updated: Thu Jul 17, 2014 08:40 am
Copyright © 2014 Topix LLC